A leading respiratory physician has welcomed the new PBS listing for omalizumab (Xolair) which will give children from six years access to the drug for severe allergic asthma. The therapy was......
PHARMACYNEWS.COM
READ MORE
|
The report, released by UK industry group the BioIndustry Association (BIA) and Informa Pharma Intelligence, shows that the UK held the largest number of clinical trials in Europe in 2017, with 351 pre-clinical trials, 43 in Phase I, 70 in Phase II, and 15 in Phase III. The next highest, France, held 192 pre-clinical trials. Some of the strength of the pipeline can be attributed to the significant amount of funding that the UK invests in early stage and translational science, the report noted. A...
READ MORE
|
An allergic reaction of any kind is a result of the immune system responding to an otherwise harmless allergen as if it were a pathogen. However, sending the right messages to the immune system can change the way it operates, as Duke University scientists found in their new study aimed at reducing the severity of food allergies....
LABROOT
READ MORE
|
Rising Pharma Holdings, Inc., f. k. a. Shore Suven Pharma, Inc., announced today that it completed the purchase of the assets of Rising Pharmaceuticals and Rising’s subsidiaries on a cash-free and debt-free basis. Shore Suven Pharma, Inc., created as an acquisition entity to acquire the assets and affiliates of Rising Pharmaceuticals, Inc. will hereafter be called, Rising Pharma Holdings, Inc. Rising Pharmaceuticals will continue to operate seamlessly and transact all business under the Ri...
READ MORE
|
Johnson & Johnson’s share price took a beating this week after the US appeals court declined its bid to stop sales of cheap generic versions of its blockbuster prostate cancer drug Zytiga. The company’s shares fell around 3% because of the court decision relating to Zytiga (abiraterone), which is the biggest-selling oncology drug from J&J’s pharma unit Janssen. In the third quarter alone Zytiga generated US sales of $527 million and the company is fighting hard to preve...
READ MORE
|
Merck’s vaunted PD-1 inhibitor Keytruda took a stumble in a late-stage trial as a treatment of patients with advanced hepatocellular carcinoma (HCC) who were previously treated with systemic therapy. In the pivotal Phase, III KEYNOTE-240 trial, Keytruda plus best supportive care failed to hit endpoints in both overall survival and progression-free survival in comparison to placebo and best supportive care. Merck said in the final analysis of the KEYNOTE-240 data there was some improvement ...
READ MORE
|